QuidelOrtho (QDEL) Cash from Financing Activities (2021 - 2026)
QuidelOrtho (QDEL) posted Cash from Financing Activities of $37.6 million for Q1 2026, up 438.74% sequentially from -$11.1 million in Q4 2025, and up 113.64% YoY from $17.6 million in Q1 2025.
QuidelOrtho (QDEL) Cash from Financing Activities (2021 - 2026) Analysis & Trends
QuidelOrtho has reported Cash from Financing Activities for 6 years, with the latest figure at $37.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 113.64% year-over-year to $37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.8 million (up 107.07% YoY) and the FY2025 annual result came in at $155.8 million, up 219.26% from the prior year.
- Cash from Financing Activities grew to $37.6 million in Q1 2026 per QDEL's latest filing, from -$11.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $424.2 million in Q1 2023 and troughed at -$99.7 million in Q3 2023.
- A 5-year average of $26.5 million and a median of -$11.1 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 1652.94% in 2023, then soared 274.9% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$3.4 million in 2022, then sank by 1600.0% to -$57.8 million in 2023, then slipped by 19.2% to -$68.9 million in 2024, then jumped by 83.89% to -$11.1 million in 2025, then surged by 438.74% to $37.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $37.6 million, -$11.1 million, and $46.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | QuidelOrtho | 1.01 Bn | 885.73 Mn | - | 200.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 200.60 Mn |
| Jun 28, 2026 | 200.60 Mn |
| Mar 29, 2026 | 37.60 Mn |
| Mar 29, 2026 | 37.60 Mn |
| Dec 28, 2025 | -11.10 Mn |
| Dec 28, 2025 | -11.10 Mn |
| Sep 28, 2025 | 46.00 Mn |
| Sep 28, 2025 | 46.00 Mn |
| Jun 29, 2025 | 103.30 Mn |
| Jun 29, 2025 | 103.30 Mn |
| Mar 30, 2025 | 17.60 Mn |
| Mar 30, 2025 | 17.60 Mn |
| Dec 29, 2024 | -68.90 Mn |
| Dec 29, 2024 | -68.90 Mn |
| Sep 29, 2024 | -26.30 Mn |
| Sep 29, 2024 | -26.30 Mn |
| Jun 30, 2024 | 162.50 Mn |
| Jun 30, 2024 | 162.50 Mn |
| Mar 31, 2024 | -18.50 Mn |
| Mar 31, 2024 | -18.50 Mn |